RLS Global AB (publ)
RLS Global AB (publ), a medical technology company, develops and sells products for minimally invasive treatment in Sweden. Its products include ChloraSolv that is used for the treatment of chronic diabetic foot and leg ulcers for diabetic patients; and CariSolv, a gel used for removing caries. RLS Global AB (publ), was founded in 1996 and is based in Mölndal, Sweden.
RLS Global AB (publ) (RLS) - Net Assets
Latest net assets as of June 2023: Skr16.61 Million SEK
Based on the latest financial reports, RLS Global AB (publ) (RLS) has net assets worth Skr16.61 Million SEK as of June 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr23.51 Million) and total liabilities (Skr6.90 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr16.61 Million |
| % of Total Assets | 70.65% |
| Annual Growth Rate | -9.15% |
| 5-Year Change | -1.5% |
| 10-Year Change | 718.57% |
| Growth Volatility | 1255.85 |
RLS Global AB (publ) - Net Assets Trend (2006–2022)
This chart illustrates how RLS Global AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for RLS Global AB (publ) (2006–2022)
The table below shows the annual net assets of RLS Global AB (publ) from 2006 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | Skr32.05 Million | +61.20% |
| 2021-12-31 | Skr19.88 Million | -34.38% |
| 2020-12-31 | Skr30.30 Million | -42.57% |
| 2019-12-31 | Skr52.76 Million | +62.14% |
| 2018-12-31 | Skr32.54 Million | -37.39% |
| 2017-12-31 | Skr51.96 Million | +1459.25% |
| 2016-12-31 | Skr3.33 Million | +22.20% |
| 2015-12-31 | Skr2.73 Million | -37.73% |
| 2014-12-31 | Skr4.38 Million | +11.87% |
| 2013-12-31 | Skr3.92 Million | -34.68% |
| 2012-12-31 | Skr5.99 Million | -4.59% |
| 2011-12-31 | Skr6.28 Million | +5064.57% |
| 2010-12-31 | Skr121.65K | -99.93% |
| 2009-12-31 | Skr175.70 Million | +42.39% |
| 2008-12-31 | Skr123.39 Million | -3.83% |
| 2007-12-31 | Skr128.30 Million | -13.81% |
| 2006-12-31 | Skr148.86 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to RLS Global AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18160800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr9.03 Million | 28.16% |
| Other Components | Skr204.63 Million | 638.51% |
| Total Equity | Skr32.05 Million | 100.00% |
RLS Global AB (publ) Competitors by Market Cap
The table below lists competitors of RLS Global AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Adroit Infotech Limited
NSE:ADROITINFO
|
$2.87 Million |
|
Zoned Properties Inc
OTCQB:ZDPY
|
$2.87 Million |
|
UET United Electronic Technology AG
XETRA:CFC
|
$2.87 Million |
|
SAFRAN - Dusseldorf Stock Exchang
DU:SEJ1
|
$2.87 Million |
|
Recharge Metals Ltd
AU:REC
|
$2.87 Million |
|
BurTech Acquisition Corp. Warrants
NASDAQ:BRKHW
|
$2.87 Million |
|
LPL FIN HLDG
BE:7LI
|
$2.87 Million |
|
Marin Software Inc
NASDAQ:MRIN
|
$2.86 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in RLS Global AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 19,881,000 to 32,048,000, a change of 12,167,000 (61.2%).
- Net loss of 24,367,000 reduced equity.
- New share issuances of 36,534,000 increased equity.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-24.37 Million | -76.03% |
| Share Issuances | Skr36.53 Million | +114.0% |
| Total Change | Skr- | 61.20% |
Book Value vs Market Value Analysis
This analysis compares RLS Global AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.96x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.01x to 0.96x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | Skr39.65 | Skr0.45 | x |
| 2007-12-31 | Skr21.14 | Skr0.45 | x |
| 2008-12-31 | Skr0.20 | Skr0.45 | x |
| 2009-12-31 | Skr24.12 | Skr0.45 | x |
| 2010-12-31 | Skr0.00 | Skr0.45 | x |
| 2011-12-31 | Skr0.47 | Skr0.45 | x |
| 2012-12-31 | Skr0.68 | Skr0.45 | x |
| 2013-12-31 | Skr0.15 | Skr0.45 | x |
| 2014-12-31 | Skr0.10 | Skr0.45 | x |
| 2015-12-31 | Skr0.06 | Skr0.45 | x |
| 2016-12-31 | Skr0.07 | Skr0.45 | x |
| 2017-12-31 | Skr0.92 | Skr0.45 | x |
| 2018-12-31 | Skr0.55 | Skr0.45 | x |
| 2019-12-31 | Skr0.86 | Skr0.45 | x |
| 2020-12-31 | Skr0.45 | Skr0.45 | x |
| 2021-12-31 | Skr0.30 | Skr0.45 | x |
| 2022-12-31 | Skr0.46 | Skr0.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently RLS Global AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -76.03%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2033.97%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.21x
- Recent ROE (-76.03%) is above the historical average (-163.09%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | -34.30% | 0.00% | 0.00x | 1.07x | Skr-65.94 Million |
| 2007 | -4.42% | -1620.86% | 0.00x | 1.51x | Skr-18.50 Million |
| 2008 | 16.41% | 18.57% | 0.59x | 1.50x | Skr7.90 Million |
| 2009 | 19.06% | 24.50% | 0.55x | 1.42x | Skr15.91 Million |
| 2010 | -866.84% | -141.71% | 0.10x | 61.78x | Skr-1.07 Million |
| 2011 | -45.09% | -368.82% | 0.10x | 1.23x | Skr-3.46 Million |
| 2012 | -131.77% | -1196.81% | 0.08x | 1.40x | Skr-8.50 Million |
| 2013 | -332.92% | -1359.50% | 0.13x | 1.89x | Skr-13.43 Million |
| 2014 | -296.65% | -981.13% | 0.19x | 1.61x | Skr-13.43 Million |
| 2015 | -325.53% | -420.63% | 0.22x | 3.46x | Skr-9.15 Million |
| 2016 | -412.81% | -477.63% | 0.23x | 3.72x | Skr-14.09 Million |
| 2017 | -37.20% | -827.38% | 0.04x | 1.14x | Skr-24.53 Million |
| 2018 | -67.28% | -835.60% | 0.07x | 1.20x | Skr-25.15 Million |
| 2019 | -51.73% | -2667.74% | 0.02x | 1.11x | Skr-32.57 Million |
| 2020 | -67.78% | -1005.09% | 0.06x | 1.16x | Skr-23.56 Million |
| 2021 | -57.63% | -1754.52% | 0.02x | 1.34x | Skr-13.45 Million |
| 2022 | -76.03% | -2033.97% | 0.03x | 1.21x | Skr-27.57 Million |
Industry Comparison
This section compares RLS Global AB (publ)'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $94,923,042
- Average return on equity (ROE) among peers: -56.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| RLS Global AB (publ) (RLS) | Skr16.61 Million | -34.30% | 0.42x | $2.87 Million |
| BioGaia AB (publ) (BIOG-B) | $230.35 Million | 33.15% | 0.21x | $714.80 Million |
| Dicot AB (DICOT) | $73.40 Million | -109.26% | 0.16x | $55.17 Million |
| Enzymatica publ AB (ENZY) | $76.61 Million | -64.91% | 0.64x | $20.94 Million |
| Enorama Pharma AB (ERMA) | $17.02 Million | -96.01% | 1.28x | $566.46K |
| Gabather AB (publ) (GABA) | $10.96 Million | -155.04% | 0.40x | $732.74K |
| Klaria Pharma Holding AB (KLAR) | $-452.69K | 0.00% | 0.00x | $15.08 Million |
| Moberg Pharma AB (publ) (MOB) | $76.79 Million | -8.31% | 0.20x | $38.42 Million |
| Nanexa AB (NANEXA) | $101.53 Million | -11.22% | 0.36x | $39.92 Million |
| Newbury Pharmaceuticals AB (NEWBRY) | $51.92 Million | -29.67% | 0.75x | $559.69K |
| Orexo AB (ORX) | $311.10 Million | -126.01% | 0.76x | $45.88 Million |